Zai Lab Limited
ZLABHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Zai Lab Limited (ZLAB) is listed under Biotechnology. With a market capitalization of $2.28B, it sits in mid-cap territory. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
Market Cap
$2.28B
Beta
0.76
P/E (TTM)
—
P/E (Fwd)
-11.57
EPS (TTM)
$-1.65
EPS (Fwd)
$-1.75
ROE
-24.2%
ROA
-13.4%
Cash
$661.3M
Total Debt
$231.9M
Free CF
-$73.4M
52W Change
-39.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $661.3M in cash comfortably exceeding the $231.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$73.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -24.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $215.0M (2022) to $460.2M (2025), reflecting a 114% increase over the period.
With cash comfortably exceeding debt, ZLAB has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ZLAB.